JP2000500479A - ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物 - Google Patents
ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物Info
- Publication number
- JP2000500479A JP2000500479A JP9519454A JP51945497A JP2000500479A JP 2000500479 A JP2000500479 A JP 2000500479A JP 9519454 A JP9519454 A JP 9519454A JP 51945497 A JP51945497 A JP 51945497A JP 2000500479 A JP2000500479 A JP 2000500479A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- alkoxy
- resulting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式: [式中、 −R1は、フッ素、ヒドロキシ、(C1−C5)アルコキシ、(C1−C5)アルキ ルチオ、ヒドロキシ(C1−C5)アルコキシ、−NR10R11基、シアノ、(C1 −C5)アルキルスルホニルまたは(C1−C5)アルキルスルフィニルであり; −R2およびR3は、(C1−C4)アルキルであるか、またはそれらが結合する窒 素原子と一緒になって5ないし10員の、飽和または不飽和の複素環残基(複素 環は、(C1−C3)アルキルまたは(C1−C3)アルコキシで置換されていない くても、一置換されていても、また多置換されていてもよい)を形成し; −R4、R5、R6、R7、R8およびR9は、それぞれ独立して、水素、ハロゲン、 またはトリフルオロメチルであり、R1がフッ素の場合には、R4、R5、R6、R7 、R8および/またはR9はフルオロメチルであってもよく、少なくともひとつ の置換基R4またはR7は水素以外である; −R10およびR11は、それぞれ独立して、水素または(C1−C5)アルキルであ るか、またはR10およびR11は、それらが結合する窒素原子と一緒になって、ピ ロリジン−1−イル、ピペリジン−1−イル、モルホリン−4−イルおよびピペ ラジン−1−イルから選択される複素環残基を形成してもよい(複素環は、(C1 −C4)アルキルで置換されていなくても置換されていてもよい) を意味する。] で表される化合物およびこれらの塩ならびに溶媒和物。 2.式:(式中、R1pは、フッ素、メトキシまたはメチルチオを意味する。)で表される 請求項1記載の化合物およびこれらの塩ならびに溶媒和物。 3.a)式: [式中、R4、R5、R6、R7、R8およびR9は請求項1における式(I)と同意 義、Rは(C1−C4)アルキルを意味する。] のブロム化エステルを式:R'1A(III)[式中、R'1は、請求項1において式 (I)について定義したR1であるか、または、R1の前駆体、Aは、水素または カチオンを意味する。]の化合物と反応させ、 b1)得られるエステルにおけるR'1を所望によりR1に変換し; b2)工程a)または工程b1)で得られる式: のエステルをけん化し; c)得られる式:の酸またはこの酸の機能的な誘導体を式:H2N−NR2R3(VI)[式中、R2お よびR3は請求項1における式(I)と同意義である。]のヒドラジンと反応さ せ; d1)得られる化合物中のR'1を所望によりR1に変換し; d2)工程c)または工程d1)で得られる式: の化合物を所望によりこれらの塩のひとつまたはこれらの溶媒和物のひとつに変 換する ことを特徴とする請求項1記載の式(I)の化合物、これらの塩およびこれらの 溶媒和物の製造方法。 4.a)式: (式中、R4、R5、R6、R7、R8、R9およびRは、請求項3と同意義である。 )のブロム化エステルをアルカリ金属またはアルカリ土類金属水酸化物と反応さ せ; b)得られる式: の酸またはこの酸の機能的な誘導体を式:H2N−NR2R3(VI)[式中、R2お よびR3は、請求項1における式(I)と同意義である。]のヒドラジンと反応 させ; c)得られる式: の化合物を式:Hal−B(式中、Halはハロゲン、Bはメシル、トシルまた はトリフルオロメタンスルホニル残基を意味する。)の化合物と反応させ; d)得られる式: の化合物を式:R1aA(XI)(式中、R1aは、上記に定義したものであり、Aは 水素またはカチオンを意味する。)と反応させ; e)得られる式:の化合物を所望によりこれらの塩のひとつまたはこれらの溶媒和物のひとつに変 換する ことを特徴とする、式中、R1=R1aであり、フッ素、(C1−C5)アルコキシ 、(C1−C5)アルキルチオ、ヒドロキシ(C1−C5)アルコキシ、シアノ、N R10R11基(ここで、R10およびR11は、請求項1における式(I)と同意義で ある。)から選択される基である、請求項1記載の式(I)の化合物を製造する 方法。 5.活性成分として、請求項1または2のいずれか一つに記載の化合物を含むこ とを特徴とする医薬組成物。 6.活性成分が少なくとも一つの医薬賦形剤と混合される投薬単位の形態である 、請求項5記載の医薬組成物。 7.0.5ないし1000mgの活性成分を含有する請求項6記載の医薬組成物 。 8.2ないし200mgの活性成分を含有する請求項7記載の医薬組成物。 9.請求項1または2のいずれか一つに記載の化合物の、化合物または放射活性 形態での、薬物学的手段としての使用。 10.式中のR1が18Fである式(I)の化合物の請求項9記載の使用。 11.カンナビノイドレセプターを単離し、精製し、解析することを可能とする リガンドの調製における、R1が水酸基またはヒドロキシ(C1−C5)アルコキ シ基である式(I)の請求項1または2のいずれか一つに記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR95/13956 | 1995-11-23 | ||
FR9513956A FR2741621B1 (fr) | 1995-11-23 | 1995-11-23 | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
PCT/FR1996/001847 WO1997019063A1 (fr) | 1995-11-23 | 1996-11-21 | Derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000500479A true JP2000500479A (ja) | 2000-01-18 |
JP2000500479A5 JP2000500479A5 (ja) | 2004-10-21 |
Family
ID=9484869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9519454A Pending JP2000500479A (ja) | 1995-11-23 | 1996-11-21 | ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6028084A (ja) |
EP (1) | EP0876350B1 (ja) |
JP (1) | JP2000500479A (ja) |
AT (1) | ATE203015T1 (ja) |
AU (1) | AU7698596A (ja) |
BR (1) | BR9611618A (ja) |
CA (1) | CA2238430C (ja) |
DE (1) | DE69613860T2 (ja) |
DK (1) | DK0876350T3 (ja) |
ES (1) | ES2161382T3 (ja) |
FR (1) | FR2741621B1 (ja) |
GR (1) | GR3036830T3 (ja) |
MX (1) | MX9803891A (ja) |
NO (1) | NO310508B1 (ja) |
PT (1) | PT876350E (ja) |
WO (1) | WO1997019063A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006501275A (ja) * | 2002-09-19 | 2006-01-12 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | カンナビノイド−cb1レセプターリガンドとしての1h−1,2,4−トリアゾール−3−カルボキシアミド誘導体 |
JP2007514638A (ja) * | 2003-06-26 | 2007-06-07 | サノフィ−アベンティス | ジフェニルピリジン誘導体、その製造法および治療用途 |
JP2008526887A (ja) * | 2005-01-10 | 2008-07-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なヘテロピロール類似体 |
JP2011506410A (ja) * | 2007-12-10 | 2011-03-03 | 7ティーエム ファーマ エイ/エス | カンナビノイド受容体モジュレーター |
JP2013500296A (ja) * | 2009-07-29 | 2013-01-07 | シーメンス アクティエンゲゼルシャフト | 活性成分および活性成分を検査するための方法 |
JP2014507425A (ja) * | 2011-09-30 | 2014-03-27 | ナショナル ヘルス リサーチ インスティテュートス | ピラゾール化合物 |
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0979228A4 (en) * | 1997-03-18 | 2000-05-03 | Smithkline Beecham Corp | CANNABINOID RECEPTOR AGONISTS |
WO1999053917A1 (en) | 1998-04-21 | 1999-10-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
DE69910373T2 (de) * | 1998-05-04 | 2004-04-01 | The University Of Connecticut, Farmington | Analgetische und immunomodulierende cannabinoiden |
US7589220B2 (en) * | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
US7897598B2 (en) * | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US7741365B2 (en) * | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
US7119108B1 (en) * | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
MXPA02005103A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Ligandos selectivos del receptor de canabinoide (cb2) perifericos. |
US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
FR2800375B1 (fr) * | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
CN1438900A (zh) * | 2000-05-23 | 2003-08-27 | 加利福尼亚大学董事会 | 一种治疗咳嗽的新方法 |
US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
EP1361876A4 (en) * | 2001-01-26 | 2004-03-31 | Univ Connecticut | NEW CANNABIMIMETIC LIGANDS |
ATE478670T1 (de) | 2001-01-29 | 2010-09-15 | Univ Connecticut | Rezeptor-selektive cannabimimetische aminoalkylindole |
US7057076B2 (en) * | 2001-07-13 | 2006-06-06 | University Of Connecticut | Bicyclic and tricyclic cannabinoids |
WO2003007887A2 (en) * | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7666867B2 (en) * | 2001-10-26 | 2010-02-23 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
WO2003063781A2 (en) * | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
NZ535349A (en) | 2002-03-08 | 2007-01-26 | Signal Pharm Inc | JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular |
NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
JP2005528366A (ja) * | 2002-03-26 | 2005-09-22 | メルク エンド カムパニー インコーポレーテッド | カンナビノイド受容体モジュレータとしてのスピロ環式アミド |
US7271266B2 (en) * | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
CA2480856A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
US7667053B2 (en) * | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
CN100486973C (zh) | 2002-07-29 | 2009-05-13 | 霍夫曼-拉罗奇有限公司 | 新苯并间二氧杂环戊烯类 |
ATE375349T1 (de) * | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
CA2496097A1 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
US7765162B2 (en) * | 2002-10-07 | 2010-07-27 | Mastercard International Incorporated | Method and system for conducting off-line and on-line pre-authorized payment transactions |
SE0203070D0 (en) * | 2002-10-16 | 2002-10-16 | Astrazeneca Ab | Novel compounds |
MXPA05004115A (es) * | 2002-10-18 | 2005-06-22 | Pfizer Prod Inc | Ligandos del receptor cannabionoide y usos de los mismos. |
ITMI20022228A1 (it) * | 2002-10-21 | 2004-04-22 | Dinamite Dipharma S P A | Sali di clopidogrel con acidi alchil-solforici. |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
MXPA05007115A (es) | 2003-01-02 | 2005-11-16 | Hoffmann La Roche | Nuevos agonistas inversos del receptor cb 1. |
EP1583742B1 (en) * | 2003-01-02 | 2009-12-02 | F. Hoffmann-La Roche Ag | Cb 1 receptour inverse agonists |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
JP2007506654A (ja) | 2003-06-20 | 2007-03-22 | エフ.ホフマン−ラ ロシュ アーゲー | Cb1受容体逆作動物質としての2−アミノベンゾチアゾール類 |
FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
EP1641493A4 (en) * | 2003-06-30 | 2007-10-31 | Merck & Co Inc | RADIOACTIVELY MARKED CANNABINOID-1 RECEPTOR MODULATORS |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
RU2361868C2 (ru) | 2003-12-08 | 2009-07-20 | Ф.Хоффманн-Ля Рош Аг | Новые производные тиазола |
TW200522944A (en) | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
JP4436369B2 (ja) | 2004-01-28 | 2010-03-24 | エフ.ホフマン−ラ ロシュ アーゲー | スピロ−ベンゾジオキソール類およびそれらのcb1アンタゴニストとしての使用 |
AU2005230864A1 (en) | 2004-03-29 | 2005-10-20 | Merck Sharp & Dohme Corp. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
DE602005014632D1 (de) | 2004-05-10 | 2009-07-09 | Hoffmann La Roche | Pyrrol- bzw. imidazolamide zur behandlung von obesitas |
ITMI20041033A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Composti farmaceutici |
ITMI20041032A1 (it) * | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
KR20070041717A (ko) | 2004-07-12 | 2007-04-19 | 카딜라 핼쓰캐어 리미티드 | 카나비노이드 수용체 조절자인 트리시클릭 피라졸 유도체들 |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
AU2005271527B2 (en) | 2004-08-06 | 2009-08-27 | Merck Sharp & Dohme Corp. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
FR2874012B1 (fr) | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
EP1784390A2 (en) * | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
ATE399156T1 (de) | 2004-10-27 | 2008-07-15 | Hoffmann La Roche | Neue indol- oder benzimidazol-derivate |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
JP4926069B2 (ja) | 2004-11-01 | 2012-05-09 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 肥満ならびに肥満関連疾患および障害の治療方法 |
BRPI0517653A (pt) | 2004-11-09 | 2008-10-14 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos |
JP2008525404A (ja) * | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療剤 |
JP2008525401A (ja) * | 2004-12-23 | 2008-07-17 | アストラゼネカ アクチボラグ | 治療薬 |
US8853205B2 (en) | 2005-01-10 | 2014-10-07 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
RU2404164C2 (ru) | 2005-04-06 | 2010-11-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридин-3-карбоксамида в качестве обратных агонистов св1 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US20060278280A1 (en) * | 2005-05-23 | 2006-12-14 | Tzai-Jen Yang | Check valve |
JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
US7923465B2 (en) * | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
KR100970055B1 (ko) * | 2005-06-22 | 2010-07-16 | 에프. 호프만-라 로슈 아게 | 6-(플루오로-벤조[1,3]디옥솔일)-모폴린-4-일-메탄온 및cb1 리간드로서 그의 용도 |
CA2518579A1 (en) * | 2005-08-05 | 2007-02-05 | University Technologies International Inc. | Method for appetite suppression |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
DE602006017712D1 (de) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
ES2381205T3 (es) | 2005-11-10 | 2012-05-24 | Msd K.K. | Derivado espiro aza-sustituido |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
ATE538650T1 (de) * | 2006-03-10 | 2012-01-15 | Jenrin Discovery | Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht |
US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
AU2007301126A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
US20080108643A1 (en) * | 2006-11-03 | 2008-05-08 | Forest Laboratories Holdings Limited | Method for treating autism |
JP5437812B2 (ja) | 2006-12-18 | 2014-03-12 | 7ティーエム ファーマ エイ/エス | Cb1受容体モジュレーター |
EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
PE20090142A1 (es) * | 2007-04-11 | 2009-02-19 | Merck & Co Inc | Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA2688161C (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8293786B2 (en) * | 2007-07-30 | 2012-10-23 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
US8133904B2 (en) * | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
BRPI0722276A2 (pt) * | 2007-11-14 | 2014-04-22 | Amylin Pharmaceuticals Inc | Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
JP5704925B2 (ja) * | 2008-02-08 | 2015-04-22 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー−カンナビノイドコンジュゲート |
US20090247619A1 (en) * | 2008-03-06 | 2009-10-01 | University Of Kentucky | Cannabinoid-Containing Compositions and Methods for Their Use |
EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | ALKYLAMINOPYRIDINE DERIVATIVE |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
US20110124674A1 (en) | 2008-07-30 | 2011-05-26 | Hiroyuki Kishino | 5/5-or 5/6-membered condensed ring cycloalkylamine derivative |
EP2149370A1 (en) | 2008-07-31 | 2010-02-03 | Neuroscienze Pharmaness S.C. A R.L. | Diazabicyclic compounds and microemulsions thereof |
IT1390848B1 (it) * | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | イソニコチンアミドオレキシン受容体アンタゴニスト |
JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
US10053444B2 (en) | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
IT1395724B1 (it) * | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
IT1394400B1 (it) | 2009-02-25 | 2012-06-15 | Neuroscienze Pharmaness S C Ar L | Composizioni farmaceutiche |
IT1394860B1 (it) | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
CA2779088A1 (en) | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
IT1396951B1 (it) * | 2009-12-18 | 2012-12-20 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
CN103664873B (zh) | 2009-12-30 | 2016-06-15 | 深圳信立泰药业股份有限公司 | 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物 |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP2958562A4 (en) | 2013-02-22 | 2016-08-10 | Merck Sharp & Dohme | BICYCLIC ANTIDIABETIC COMPOUNDS |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2789619A1 (en) | 2013-04-12 | 2014-10-15 | Kemotech S.r.l. | Pharmaceutical compounds wiht angiogenesis inbhibitory activity |
CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015188073A1 (en) | 2014-06-06 | 2015-12-10 | Research Triangle Institute | Apelin receptor (apj) agonists and uses thereof |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
US10100059B2 (en) | 2015-12-09 | 2018-10-16 | Research Triangle Institute | Apelin receptor (APJ) agonists and uses thereof |
AR109950A1 (es) | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
TW202033516A (zh) | 2018-11-20 | 2020-09-16 | 義大利商Tes製藥(股份)責任有限公司 | α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑 |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
EP4200295A1 (en) | 2020-08-18 | 2023-06-28 | Merck Sharp & Dohme LLC | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3449350A (en) * | 1968-06-24 | 1969-06-10 | Ciba Geigy Corp | Certain pyrazole-3-carboxylic acid hydrazide derivatives |
FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
-
1995
- 1995-11-23 FR FR9513956A patent/FR2741621B1/fr not_active Expired - Fee Related
-
1996
- 1996-11-21 ES ES96939962T patent/ES2161382T3/es not_active Expired - Lifetime
- 1996-11-21 DK DK96939962T patent/DK0876350T3/da active
- 1996-11-21 CA CA002238430A patent/CA2238430C/en not_active Expired - Fee Related
- 1996-11-21 AT AT96939962T patent/ATE203015T1/de not_active IP Right Cessation
- 1996-11-21 DE DE69613860T patent/DE69613860T2/de not_active Expired - Lifetime
- 1996-11-21 EP EP96939962A patent/EP0876350B1/fr not_active Expired - Lifetime
- 1996-11-21 WO PCT/FR1996/001847 patent/WO1997019063A1/fr active IP Right Grant
- 1996-11-21 AU AU76985/96A patent/AU7698596A/en not_active Abandoned
- 1996-11-21 JP JP9519454A patent/JP2000500479A/ja active Pending
- 1996-11-21 PT PT96939962T patent/PT876350E/pt unknown
- 1996-11-21 BR BR9611618A patent/BR9611618A/pt not_active Application Discontinuation
- 1996-11-21 US US09/068,869 patent/US6028084A/en not_active Expired - Lifetime
-
1998
- 1998-05-15 MX MX9803891A patent/MX9803891A/es unknown
- 1998-05-22 NO NO19982330A patent/NO310508B1/no unknown
-
2001
- 2001-10-08 GR GR20010401691T patent/GR3036830T3/el not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006501275A (ja) * | 2002-09-19 | 2006-01-12 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | カンナビノイド−cb1レセプターリガンドとしての1h−1,2,4−トリアゾール−3−カルボキシアミド誘導体 |
JP2007514638A (ja) * | 2003-06-26 | 2007-06-07 | サノフィ−アベンティス | ジフェニルピリジン誘導体、その製造法および治療用途 |
JP4669839B2 (ja) * | 2003-06-26 | 2011-04-13 | サノフィ−アベンティス | ジフェニルピリジン誘導体、その製造法および治療用途 |
JP2008526887A (ja) * | 2005-01-10 | 2008-07-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なヘテロピロール類似体 |
JP2011506410A (ja) * | 2007-12-10 | 2011-03-03 | 7ティーエム ファーマ エイ/エス | カンナビノイド受容体モジュレーター |
JP2013500296A (ja) * | 2009-07-29 | 2013-01-07 | シーメンス アクティエンゲゼルシャフト | 活性成分および活性成分を検査するための方法 |
JP2014507425A (ja) * | 2011-09-30 | 2014-03-27 | ナショナル ヘルス リサーチ インスティテュートス | ピラゾール化合物 |
US8962845B2 (en) | 2011-09-30 | 2015-02-24 | National Health Research Institutes | Pyrazole compounds |
Also Published As
Publication number | Publication date |
---|---|
ATE203015T1 (de) | 2001-07-15 |
NO310508B1 (no) | 2001-07-16 |
PT876350E (pt) | 2001-12-28 |
CA2238430A1 (en) | 1997-05-29 |
GR3036830T3 (en) | 2002-01-31 |
DE69613860T2 (de) | 2002-04-04 |
EP0876350B1 (fr) | 2001-07-11 |
MX9803891A (es) | 1998-09-30 |
FR2741621B1 (fr) | 1998-02-13 |
US6028084A (en) | 2000-02-22 |
CA2238430C (en) | 2006-05-09 |
DK0876350T3 (da) | 2001-11-05 |
DE69613860D1 (de) | 2001-08-16 |
ES2161382T3 (es) | 2001-12-01 |
NO982330L (no) | 1998-05-22 |
BR9611618A (pt) | 1999-03-30 |
FR2741621A1 (fr) | 1997-05-30 |
AU7698596A (en) | 1997-06-11 |
NO982330D0 (no) | 1998-05-22 |
WO1997019063A1 (fr) | 1997-05-29 |
EP0876350A1 (fr) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000500479A (ja) | ピラゾール誘導体、その製造方法、および該誘導体を含む医薬組成物 | |
JP3825062B2 (ja) | 新規なピラゾール−3−カルボキサミド誘導体、これらを製造するための方法及びこれらが存在する薬学的組成物 | |
JP4964380B2 (ja) | ピラゾールカルボン酸の三環式誘導体、その製造法およびそれを含む医薬組成物 | |
JP3510270B2 (ja) | カンナビノイド受容体親和性を有する3―ピラゾールカルボキサミド誘導体 | |
JP3995405B2 (ja) | 置換されたn−ピペリジノ−ピラゾール−3−カルボキサミド | |
AU754771B2 (en) | Pyrazolecarboxylic acid derivatives, their preparation, pharmaceutical compositions containing them | |
JP3238801B2 (ja) | 新規なピラゾール誘導体、それらを調製する方法、及びこれらを含有する薬学的組成物 | |
US5968944A (en) | Substituted pyrazoles as corticotropin-releasing factor (CRF) antagonists | |
EP0674631B1 (en) | Substituted pyrazoles as crf antagonists | |
JP4944329B2 (ja) | カンナビノイドレセプターのアンタゴニストとしての1−ベンジルピラゾール−3−カルボン酸の三環式誘導体 | |
AU654350B2 (en) | Benzofuran derivatives | |
JPH11507937A (ja) | Cb2受容体作用化合物 | |
PT868364E (pt) | Metodo para formar uma embalagem de abertura facil para uma pluralidade de recipientes | |
JP2707936B2 (ja) | β−オキソ−β−ベンゼンプロパンチオアミド誘導体 | |
JP3794696B2 (ja) | フェニルイミダゾリジノン誘導体およびその製造法 | |
JP2001510481A (ja) | インダン様化合物の製造方法 | |
FR2789078A1 (fr) | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041229 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070807 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071225 |